Description: Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Home Page: ikenaoncology.com
IKNA Technical Analysis
645 Summer Street
Boston,
MA
02210
United States
Phone:
857 273 8343
Officers
| Name | Title |
|---|---|
| Dr. Mark Manfredi Ph.D. | Pres. CEO & Director |
| Dr. Sergio L. Santillana M.B.A., M.D., M.Sc., MSc | Chief Medical Officer |
| Dr. Jotin Marango M.D., Ph.D. | CFO & Head of Corp. Devel. |
| Dr. Michelle Zhang Ph.D. | Chief Scientific Officer |
| Ms. Samantha Vuksanic | Head of HR |
| Mr. Jeffrey Ecsedy Ph.D. | Chief Devel. Officer |
| Mr. Alfredo Castro Ph.D. | Exec. VP of Discovery |
| Mr. Alexander Constan Ph.D. | Sr. VP of Non Clinical Safety & DMPK |
| Ms. Jennifer Schroeder | Sr. VP of Clinical Devel. Operations |
| Mr. Evan A. Hecker Ph.D. | Sr. VP & Head of CMC |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 3.95 |
| Price-to-Book MRQ: | 0.6599 |
| Price-to-Sales TTM: | 3.1264 |
| IPO Date: | 2021-03-26 |
| Fiscal Year End: | December |
| Full Time Employees: | 78 |